Alnylam Pharmaceuticals Net Income 2006-2021 | ALNY

Alnylam Pharmaceuticals annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Alnylam Pharmaceuticals net income for the quarter ending June 30, 2021 was $-0.190B, a 5.76% increase year-over-year.
  • Alnylam Pharmaceuticals net income for the twelve months ending June 30, 2021 was $-0.887B, a 4.79% increase year-over-year.
  • Alnylam Pharmaceuticals annual net income for 2020 was $-0.858B, a 3.14% decline from 2019.
  • Alnylam Pharmaceuticals annual net income for 2019 was $-0.886B, a 16.37% increase from 2018.
  • Alnylam Pharmaceuticals annual net income for 2018 was $-0.761B, a 55.13% increase from 2017.
Alnylam Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-858
2019 $-886
2018 $-761
2017 $-491
2016 $-410
2015 $-290
2014 $-360
2013 $-89
2012 $-106
2011 $-58
2010 $-44
2009 $-48
2008 $-26
2007 $-85
2006 $-35
2005 $-43
Alnylam Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-06-30 $-190
2021-03-31 $-200
2020-12-31 $-244
2020-09-30 $-253
2020-06-30 $-179
2020-03-31 $-182
2019-12-31 $-276
2019-09-30 $-209
2019-06-30 $-219
2019-03-31 $-182
2018-12-31 $-211
2018-09-30 $-245
2018-06-30 $-164
2018-03-31 $-141
2017-12-31 $-142
2017-09-30 $-123
2017-06-30 $-118
2017-03-31 $-107
2016-12-31 $-113
2016-09-30 $-104
2016-06-30 $-90
2016-03-31 $-103
2015-12-31 $-91
2015-09-30 $-77
2015-06-30 $-72
2015-03-31 $-51
2014-12-31 $-21
2014-09-30 $-44
2014-06-30 $-44
2014-03-31 $-251
2013-12-31 $-32
2013-09-30 $-30
2013-06-30 $-18
2013-03-31 $-9
2012-12-31 $-62
2012-09-30 $-20
2012-06-30 $-13
2012-03-31 $-11
2011-12-31 $-14
2011-09-30 $-13
2011-06-30 $-14
2011-03-31 $-16
2010-12-31 $-7
2010-09-30 $-10
2010-06-30 $-15
2010-03-31 $-12
2009-12-31 $-8
2009-09-30 $-9
2009-06-30 $-23
2009-03-31 $-8
2008-12-31 $-9
2008-09-30 $-3
2008-06-30 $-13
2008-03-31 $-1
2007-12-31 $2
2007-09-30 $-53
2007-06-30 $-13
2007-03-31 $-22
2006-12-31 $7
2006-09-30 $-7
2006-06-30 $-10
2006-03-31 $-9
2005-12-31 $-14
2005-09-30 $-11
2005-06-30 $-11
2005-03-31 $-7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $22.719B $0.493B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67